Related Experiment Video
Updated: Oct 30, 2025

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
A successful case of extracorporeal membrane oxygenation for COVID-19: walking home without oxygen supplementation
Dena H Tran1, Carol Chiung-Hui Peng1, Daniel A Wolde-Rufael1,2
1Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, MD, USA.
Insights
Extracorporeal membrane oxygenation (ECMO) may be an effective salvage therapy for severe acute respiratory distress syndrome (ARDS) caused by COVID-19. A case study showed a patient recovered fully after 35 days of veno-venous ECMO and rehabilitation.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Pulmonology
Background:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, frequently leading to intensive care unit admission and acute respiratory distress syndrome (ARDS).
- Extracorporeal membrane oxygenation (ECMO) is a salvage therapy for severe ARDS, but its role in COVID-19 remains under investigation.
Purpose of the Study:
- To present a case of successful Extracorporeal Membrane Oxygenation (ECMO) use in a patient with severe COVID-19-induced acute respiratory distress syndrome (ARDS).
- To highlight the potential of ECMO as a salvage therapy for critical COVID-19 cases.
Main Methods:
- A case presentation of a previously healthy 39-year-old male with progressive pneumonia and ARDS due to COVID-19.
- Management included prone positioning, convalescent plasma, and 35 days of veno-venous ECMO (VV-ECMO).
- The patient underwent aggressive mobility-focused rehabilitation during hospitalization.
Main Results:
- The patient successfully recovered from severe ARDS caused by COVID-19.
- Discharged from the hospital on day 63, ambulating independently without oxygen supplementation.
- Demonstrated the feasibility and positive outcome of prolonged VV-ECMO support.
Conclusions:
- This case suggests ECMO can be an effective salvage treatment for severe ARDS in COVID-19 patients.
- Aggressive rehabilitation is crucial for functional recovery after prolonged ECMO therapy.
- Further research is warranted to establish ECMO's definitive role in managing critical COVID-19.
Abstract:
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged from Wuhan, China in December 2019 and is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19). Approximately one-third of the patients with COVID-19 require intensive care unit (ICU) admission, and almost 30% of the patients develop acute respiratory distress syndrome (ARDS). Extracorporeal membrane oxygenation (ECMO) is used as salvage therapy for severe ARDS. The role of ECMO in the treatment of COVID-19 remains unclear, although there is emerging evidence that this approach may be an effective salvage therapy for severe ARDS. Case Presentation: We present a case of a previously healthy 39-year-old Hispanic male who presented to the hospital with flu-like symptoms, including headache, fatigue, and myalgia for 8 days in late April 2020. He denied dyspnea on exertion. The patient's symptoms progressed, resulting in pneumonia and acute respiratory distress syndrome (ARDS). The patient was managed with prone positioning, convalescent plasma and veno-venous extracorporeal membrane oxygenation (VV-ECMO) for 35 days. The patient successfully recovered and was able to ambulate independently and was discharged home from an acute care hospital without oxygen supplementation on hospital day 63. Conclusion: We present one of the first few documented cases of ECMO for severe ARDS due to COVID-19. After a prolonged hospital course requiring VV-ECMO, the patient was discharged home from an acute care hospital without oxygen requirement and ambulated independently, likely as a result of daily aggressive mobility-focused rehabilitation.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen Delivering System II: Venturi Mask and Transtracheal Oxygen
Venturi Mask
The Venturi mask, named after the Venturi effect, is designed to deliver precise oxygen concentrations. It consists of a large tube with an oxygen inlet that narrows down, causing a pressure drop that pulls air in through adjustable side ports. The mask is a lightweight,...
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Oxygen Delivering System I: Nasal Cannula and Face Mask
Nasal Cannula
A nasal cannula is a lightweight tube split at one end into two prongs and placed in the nostrils. It is typically used to deliver low to medium levels of oxygen.
Suggested flow rate: The suggested flow rate for a nasal cannula typically ranges between 1 and 6 L/min.
Oxygen percentage setting:...

